Simplicity Solutions LLC Has $11.24 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Simplicity Solutions LLC decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 15.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 48,577 shares of the medical research company's stock after selling 8,830 shares during the period. Simplicity Solutions LLC's holdings in IQVIA were worth $11,240,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Norges Bank purchased a new position in shares of IQVIA during the fourth quarter worth approximately $408,232,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in shares of IQVIA by 1,852.5% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,066,764 shares of the medical research company's stock worth $423,466,000 after buying an additional 1,960,914 shares during the period. Alliancebernstein L.P. lifted its position in IQVIA by 19.1% during the second quarter. Alliancebernstein L.P. now owns 5,942,761 shares of the medical research company's stock valued at $1,335,754,000 after purchasing an additional 952,850 shares during the period. AMF Tjanstepension AB acquired a new position in IQVIA during the third quarter valued at $148,096,000. Finally, Eagle Asset Management Inc. acquired a new position in IQVIA during the third quarter valued at $102,982,000. Institutional investors own 89.62% of the company's stock.

IQVIA Trading Down 1.6 %

NYSE:IQV traded down $3.79 on Friday, hitting $234.23. The stock had a trading volume of 932,313 shares, compared to its average volume of 750,724. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12. The stock has a market cap of $42.51 billion, a price-to-earnings ratio of 32.13, a PEG ratio of 2.27 and a beta of 1.50. The company has a fifty day moving average price of $243.47 and a two-hundred day moving average price of $220.87. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.02. The company had revenue of $3.87 billion for the quarter, compared to analyst estimates of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. IQVIA's revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the business posted $2.54 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IQV has been the subject of a number of analyst reports. SVB Leerink initiated coverage on shares of IQVIA in a research report on Monday, February 26th. They issued an "outperform" rating and a $290.00 price objective for the company. Robert W. Baird upped their price objective on shares of IQVIA from $226.00 to $251.00 and gave the stock a "neutral" rating in a research report on Thursday, February 15th. Guggenheim cut shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Thursday, February 15th. UBS Group boosted their target price on shares of IQVIA from $240.00 to $300.00 and gave the stock a "buy" rating in a research note on Thursday, February 15th. Finally, Leerink Partnrs reissued an "outperform" rating on shares of IQVIA in a research note on Monday, February 26th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $256.80.

Insider Transactions at IQVIA

In other news, insider Kevin C. Knightly sold 8,607 shares of the company's stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the transaction, the insider now directly owns 5,251 shares in the company, valued at approximately $1,313,642.67. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Eric Sherbet sold 1,000 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the transaction, the insider now directly owns 20,836 shares of the company's stock, valued at approximately $5,031,894. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the transaction, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The disclosure for this sale can be found here. In the last three months, insiders have sold 41,285 shares of company stock worth $10,331,003. 1.60% of the stock is currently owned by insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.